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Guidelines are an important means by which professional associations and governments
have sought to improve the quality and cost-effectiveness of disease management for
infectious diseases. Prescribing of initial antibiotic therapy for community-acquired
respiratory tract infections (RTIs) is primarily empiric and physicians may often have
a limited appreciation of bacterial resistance. Recent guidelines for managing RTIs have
adopted a more evidence-based approach. This process has highlighted important gaps
in the existing knowledge base, e.g. concerning the impact of resistance on the effec-
tiveness of oral antibiotics for outpatient community-acquired pneumonia and the level
of resistance that should prompt a change in empiric prescribing. In upper RTIs, the
challenge is to identify patients in whom antibiotic therapy is warranted. Concentrated,
sustained efforts are needed to secure physicians’ use of guidelines. The information
should be distilled into a simple format available at the point of prescribing and
supported by other behavioral change techniques (e.g. educational outreach visits).
Advances in information technology offer the promise of more dynamic, computer-
assisted forms of guidance. Thus, RTI prescribing guidelines and other prescribing
support systems should help control bacterial resistance in the community. However,
their effect on resistance patterns is largely unknown and there is an urgent need for
collaborative research in this area. Rapid, cost-effective diagnostic techniques are also
required and new antibiotics will continue to have a role in disease management.
Keywords Antibiotic, prescribing guidelines, respiratory tract infections, pneumonia,
otitis media, sinusitis
INTRODUCTION
Guidelines have become an important means by
which professional associations and governments
have sought to improve the quality and cost-effec-
tiveness of disease management in many thera-
peutic areas, including infectious diseases. The
control of bacterial resistance has largely been a
secondary issue in developing guidelines for
managing infectious disease. However, the epide-
miology of bacterial resistance patterns is an
important inﬂuence on the development of such
guidelines and, by encouraging prudent antimi-
crobial use, guidelines may help to reduce the
clinical impact and spread of resistance.
Here, we explore the physician’s perspective in
treating common community-acquired respiratory
tract infections (RTIs)—namely community-
acquired pneumonia (CAP), pharyngitis, sinusitis
and otitis media—in this era of increasing bacterial
resistance. We focus in particular on how guide-
lines and other prescribing support systems can
better relate resistance and disease management.
We outline the challenges inherent in the devel-
opment, implementation and audit of guidelines
and other systems, review what can be learned
from the experience gained through these efforts,
and consider how information technology can be
applied to improve decision-making in the future.
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THE NEED FOR PRESCRIBING
SUPPORT
Physicians are the ﬁnal distributors of antibiotics
in most countries where drug prescribing is pro-
fessionally controlled (i.e. where such drugs are
unavailable over the counter). As such, they tend
to be regarded as the culprits responsible for
antibiotic overuse and, in turn, the spread of bac-
terial resistance. Imprudent prescribing may
involve the use of the wrong antibiotic, dosage,
or treatment duration or, more fundamentally, the
use of an antibiotic when none is necessary. This
last aspect is particularly pertinent to the manage-
ment of RTIs in the community, where large quan-
tities of antibiotics are prescribed unnecessarily for
viral RTIs [1–3]. However, physicians must bal-
ance professional and societal concerns about anti-
biotic resistance with their responsibility for
managing and preventing infectious diseases in
the individual patient. Therefore it is crucial that
the risk–beneﬁt ratio be considered when selecting
to prescribe an antibiotic. The clinical beneﬁt of
therapy and the risks in terms of the development
and spread of bacterial resistance (as well as those
of allergy, adverse events and drug interactions)
must be understood. Conversely, when designing
interventions to control antibiotic usage, any ben-
eﬁcial effects on resistance control must be
balanced against the risk of adverse disease out-
comes when appropriate antibiotic therapy is
withheld. In brief, the phrase ‘prudent prescribing’
requires careful deﬁnition.
To this end, it is important to know which
patients and which conditions truly beneﬁt from
antibiotic therapy. This situation differs between
different RTIs, aswill be discussed. Furthermore, it
is important to know which patients are likely to
have infections with resistant organisms. It is dif-
ﬁcult to recognize reliably resistance at the point of
prescribing by clinical means, particularly in com-
munity practice where antibiotic prescribing is
primarily empiric and is initiated in the absence
of microbiologically deﬁned illness. An indirect,
nonspeciﬁc assessment of bacterial resistance is
the use of clinical treatment failure, i.e. in pati-
ents who have not responded to initial antibiotic
therapy, provided it was appropriate and that
the patient adhered to the treatment regimen.
However, this type of assessment—based on rela-
tively imprecise data that may be affected by
patient demography and co-morbidity, as well
as previous therapy—is not an ideal basis for a
prescribing policy.
From the prescribing perspective, there is also
the issue of the deﬁnition of resistance. The inter-
relationship between humans and bacteria in this
context is the clinical expression of disease. The
problem is primarily one of managing resistant
infections, rather than resistant bacteria. As we
will discuss, in vitro deﬁnitions of resistance do
not always correlate well with clinical outcomes.
This results in a credibility gap between prescri-
bers and epidemiologic data on resistance trends.
Clinical guidelines are one type of decision-
support system that have been developed to help
physicians deal with these issues.
COMMUNITY-ACQUIRED
PNEUMONIA
Most patients with CAP have mild-to-moderate
disease that can be treated in the community. We
will focus on this group, because antibiotic pre-
scribing in this setting remains largely empiric,
both initially and throughout the period of drug
management. The importance of correct outpatient
antibiotic management is underscored by the
poorer clinical outcomes and substantially higher
treatment costs in patients who fail outpatient
treatment and subsequently require admission
to hospital [4,5].
Numerous guidelines for CAP management
have been published since the early 1990s. Pre-
vious inﬂuential guidelines from North America
have included those of the American Thoracic
Society (ATS) [6], the Infectious Disease Society
of America (IDSA) [7] and the Canadian Commu-
nity-Acquired Pneumonia Consensus Conference
Group [8]. Among European guidelines, those of
the British Thoracic Society (BTS) [9] have been
widely adopted and inﬂuential, although other
guidelines have been published in many other
countries,e.g.France[10,11],Spain[12,13],Germany
[14], Switzerland [15] and by the European Respi-
ratory Society [16]. Recommendations have also
been issued in South Africa [17], Japan [18,19] and
Australia [20].
Since treatment guidelines must reﬂect the latest
etiologic data, resistance surveillance data and
clinical experience with antibacterials, many of
these guidelines have recently been revised, i.e.
those of the IDSA [21], ATS [22], Canadian groups
[23] and the BTS [24]. The United States Centers for
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Disease Control and Prevention (CDC) have also
issued new guidelines speciﬁcally in response to
the spread of resistance in Streptococcus pneumoniae
[25].
The contrast in the manner by which guidelines
have been developed in recent years, as compared
with previous years, is striking. Earlier guidelines
were based on limited and outdated microbiologic
data and were opinion-based rather than evi-
dence-based. That is, experts provided consensus
recommendations based on their knowledge and
experience of a particular area of medicine. The
scientiﬁc basis for these ‘eminence-based’ recom-
mendations was often not particularly strong. In
line with the general trend in medical science,
guidelines are now developed using a more rig-
orous, evidence-based approach. According to this
method, all relevant evidence is evaluated and
graded according to established criteria for quality
before being analyzed and integrated into the
guidelines. The evidence levels applied in the
development of the BTS guidelines are summar-
ized in Table 1; other bodies have used similar
stratiﬁcations [21–23]. In addition to providing a
more rigorous foundation for guidelines, this
approach serves to highlight systematically gaps
in the existing knowledge base (Table 2). This can
be helpful in guiding future research. In the mean-
time, current guidelines must utilize existing data,
while acknowledging the limited evidence on
which some recommendations will inevitably be
based.
Definition of disease
The starting point in the development of disease
management guidelines is a clear deﬁnition of the
condition in question that is widely accepted and
readily achievable. While the diagnosis of pneu-
monia managed in the hospital is based on clinical
features supported by radiographic examination,
outpatient pneumonia is primarily clinically
deﬁned. In the USA, guidelines recommend that
patients with suspected pneumonia undergo chest
radiography [21,22]. However, in many other
Table 1 Definitions of evidence levels used in the devel-
opment of the British Thoracic Society guidelines for the
management of community-acquired pneumonia [24]
Evidence type
Evidence
level
Evidence
grade
Good recent systematic review
of studies
Ia Aþ
Prospective study with multivariate
analysis, prospective validation
study
Ib A
Prospective study with univariate
analysis
II Bþ
Retrospective study with
multivariate or univariate
analysis, retrospective validation
study
III B
Formal combination of expert views IVa C
Expert opinion, informal consensus IVb D
Table 2 Major outstanding gaps in knowledge relating to the management of community-acquired pneumonia
Issue Comments
Bacterial etiology Few documented outpatient infections
Bacterial cause not established in 40% of infections
Improved microbiologic diagnostic techniques are required to rapidly identify the
pathogen and its antibacterial susceptibility
Impact of resistance on
clinical/bacteriologic outcome
Effect of high-level penicillin and erythromycin resistance in Streptococcus pneumoniae
on treatment efficacy is unclear. Need for:
prospective data on effectiveness of treatment in microbiologically documented
resistant infections data on impact of inappropriate vs. appropriate therapy;
definition of threshold resistance prevalence that necessitates a change in empiric
prescribing
Optimal drug therapy Need studies designed to assess relative efficacy of new agents compared with older
agents
Definition of optimal drug
dosage and treatment duration
Few studies have been designed to determine optimal dosage and duration
Recommended dosages vary between countries
Optimal means of
implementing guidelines
Current evidence shows highly variable effectiveness of different approaches
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countries it is unusual for outpatients with CAP to
receive an X-ray, and in these circumstances diag-
nosis is based solely on clinical criteria.
The evidence base validating the sensitivity,
speciﬁcity and variability of the clinical diagnosis
of pneumonia has been questioned [23]. However,
studies have supported the clinical deﬁnition of
outpatient pneumonia on the basis of cough and
other RTI symptoms, systemic symptoms and the
presence of new focal chest signs on examination
[24].
Microbial etiology
Internationally, S. pneumoniae is generally consid-
ered to be the most common single cause of CAP,
particularly in patients requiring hospitalization
[15,16,21–24]. However, few studies have speciﬁ-
cally investigated the microbial etiology of CAP in
patients treated as outpatients. During the devel-
opment of the revised BTS guidelines, only eight
studies—involving 1039 documented infections—
were considered to have suitable data on outpa-
tient-managed disease. Moreover, the microbial
etiology was not established in almost half of
the patients studied. Even this proportion is an
overestimation of the usual situation in clinical
practice in the community, because an etiologic
agent is only identiﬁed in around 25% of cases
after the patient is admitted to hospital. Clearly,
this is an inadequate evidence base for such a
pivotal aspect of disease management and more
research is urgently required to improve the accu-
racy of CAP diagnosis in outpatients.
In the UK, S. pneumoniae is regarded as themajor
pathogen causing CAP in outpatients and is the
target governing initial empiric antibiotic therapy.
The so-called ‘atypical’ pathogens, which include
Chlamydia pneumoniae, Legionella pneumophila and
Chlamydia psittaci, are generally considered
uncommon. Mycoplasma pneumoniae has been
identiﬁed in up to 37% of cases in surveys of
outpatient CAP [26–28], but is much less common
during interepidemic years. Mycoplasma pneumo-
niae epidemics occur only about once every 4 or
5 years. Moreover, M. pneumoniae infection is sea-
sonal and usually associated with mild CAP in the
younger adult. It is often not recognized because of
the serologic tests required. Chlamydia pneumoniae
is also a common cause of mild CAP in young
people. However, there is no readily available,
rapid diagnostic test for this infection, leaving only
serology to document its past occurrence. While
there are no wholly satisfactory serologic methods
for the diagnosis of C. pneumoniae infections, the
microimmunoﬂuorescence (MIF) test, when it is
properly performed and when its results are prop-
erly read, provides the most sensitive and species-
speciﬁc method for laboratory diagnosis of acute
infection [29]. TheMIF test is the only antibody test
available that measures the titers of speciﬁc anti-
bodies to all species simultaneously. The disad-
vantages of the MIF test are that the end-point
ﬂuorescence (or the titer) is determined subjec-
tively, the test has low throughput, and the test
requires proﬁciency and experience for correct
reading of the end-point titers [30].
Legionella pneumophila is an important cause of
severe pneumonia and in exceptional circum-
stances outbreaks may occur. However, it is an
uncommon cause of CAP in patients managed
as outpatients [24]. Atypical pathogens (especially
S. pneumoniae) are regarded as more important
potential pathogens in North America than they
are in the UK [21–23]. Further research is required
to deﬁne the importance of these agents in the
etiology of pneumonia in outpatients, as well as
in relation to disease in patients who are hos-
pitalized, as the need for coverage against them
is an important inﬂuence on the choice of therapy.
There is a particular need for better diagnostic
techniques to identify S. pneumoniae in the com-
munity at the time of initial assessment. Like-
wise, the importance of viral infections, such as
inﬂuenza and respiratory syncytial virus occur-
ring either as single infections or as part of a
polymicrobial pneumonia, needs to be deﬁned
[24].
Haemophilus inﬂuenzae remains an uncommon
cause of CAP and, although b-lactamase produc-
tion ranges from 10 to 30%, infections caused by
encapsulated strains have become less important
as a cause of bacteremic CAP since the introduc-
tion of the H. inﬂuenzae type b (Hib) vaccine. The
Hib vaccine has dramatically reduced invasive
H. inﬂuenzae type b, but has not had an impact
on mucosal disease. Mucosal disease includes oti-
tis media and sinusitis and is largely caused by
nontypeable H. inﬂuenzae. Invasive disease inc-
ludes meningitis and pneumonia. Prior to the
Hib vaccine era, half of the cases of these infections
were caused by serotype b [31]. Since the intro-
duction of Hib vaccination of infants there has
been a dramatic reduction in the number of cases
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ofmeningitis caused byH. inﬂuenzae in children, as
well as in invasive H. inﬂuenzae disease in adults
[32].
Antibiotic management
Ideally, the selection of an antibiotic to treat any
infection should be based on microbiologic iden-
tiﬁcation of the causative pathogen and its anti-
biotic-susceptibility proﬁle. However, this is
unrealistic in the outpatient management of
CAP owing to the delays involved, the low yield
of bacterial isolates, the fact that such tests have
shown minimal value in outpatients, and because
of the economic impact of these investigations.
Therefore current guidelines agree that microbio-
logic assessment is inappropriate in patients with
CAP who are managed as outpatients [21,23,24],
although a sputum Gram stain and culture may be
appropriate if infection by a resistant pathogen or
a pathogen not covered by the usual empiric
antibiotic regimens is suspected [22]. The selection
of initial antibiotic treatment must therefore be
‘empiric’, i.e. based on knowledge of the likely
pathogens and their antibiotic susceptibility, to-
gether with patient factors (e.g. previous drug tole-
ration, allergy) and cost. Although this strategy is
currently in operation, it is ultimately untenable for
effective resistance control. Effortsmust continue to
be directed toward the development of diagnostic
teststhatallowmorerapidandreliableidentiﬁcation
of the pathogen at the point of prescribing. This
information should then be interpreted according
to local surveillance data to predict the likely sus-
ceptibility of the pathogen. Laboratory practices
should be standardized to improve the quality
and timeliness of reporting so that these data can
inﬂuence prescribing more effectively.
Evidence base for antibiotic management
The evidence base for the antibiotic management
of CAP remains limited and is largely derived
from commercially funded studies in support of
licensing applications for new antibiotics. Of the 85
studies that were reviewed during the develop-
ment of the BTS guidelines, only 16 provided
acceptable evidence considered suitable for inclu-
sion. The others were rejected because the drug
was either an investigational agent or was not
available in the UK, the study population was
substantially different from those managed in
the UK, or the trials had design ﬂaws.
Although most trials currently performed by
pharmaceutical companies for drug licensing pur-
poses are generally large and well conducted, they
are often powered to demonstrate equivalence
with an established comparator regimen. Hence,
these trials give no information as to whether
newer antibiotics are superior to older agents
and consequently do not advance our knowledge
concerning optimal therapy. Generic off-patent
agents (e.g. older b-lactams and macrolides such
as erythromycin) account for a large proportion of
antibiotic use and there is little incentive for indus-
try to evaluate these agents. A major research
effort is essential if the evidence base used to
deﬁne the optimal therapeutic management of
CAP is to be improved. This will require health-
care professionals, those who fund health-care
systems, grant-giving bodies, and the pharmaceu-
tical industry to work co-operatively.
Recommended therapy
How have the different expert groups interpreted
the available evidence on antibiotic management?
Onemight expectdifferent groupsof expertswithin
the same ﬁeld andwith access to the same evidence
base to draw similar conclusions and make similar
recommendations. The recommendations for initial
empiric outpatient therapy from the IDSA [21], the
ATS [22], and the Canadian CAP Working Group
[23] are indeed rather similar (Table 3). These favor
the use of macrolides and doxycycline. Macrolides
have been preferred for outpatient CAP in North
America for the last decade because of their activity
against atypical organisms aswell as—to a variable
extent—S. pneumoniae [6,8].
The IDSA guidelines include the newer ‘respira-
tory’ ﬂuoroquinolones (e.g. levoﬂoxacin, gatiﬂox-
acin, moxiﬂoxacin) among the three antimicrobial
classes recommended for ﬁrst-line therapy for
outpatient-managed CAP [21]. In contrast, the
ATS and Canadian guidelines reserve these agents
for more complicated patients with cardiopulmon-
ary disease and/or other modifying factors [22,23].
For example, the Canadian guidelines specify their
use in patients with chronic obstructive lung dis-
ease who have received recent treatment with
antibiotics or treatment with oral corticosteroids
within the previous 3months [23]. Both of these
guidelines also recommend extended-spectrum b-
lactams used in combination with macrolides or
doxycycline as alternative regimens in patients
with modifying factors.
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The BTS guidelines [24] differ signiﬁcantly from
the North American guidelines. Although atypical
organisms are recognized as occasional causes of
CAP, S. pneumoniae remains the main focus in
deﬁning recommended therapy in the BTS guide-
lines. Indeed, the decision is disease management-
focused and based on distinguishing severe CAP
from nonsevere CAP, which is usually managed in
the community. Atypical pathogens only account
for 3% of all pneumonias managed in the commu-
nity. This acknowledges that many microbiologi-
cally undocumented infections (which account for
approximately half of all CAP infections) are pre-
sumptively pneumococcal in nature, while the
true incidence of CAP caused by S. pneumoniae
in the community has yet to be deﬁned. The
BTS guidelines therefore continue to recommend
amoxicillin for ﬁrst-line antibiotic treatment of
outpatient CAP, but at an increased daily dosage
to accommodate for the trend towards reduced
susceptibility among pneumococci. Macrolides are
reserved for penicillin-allergic patients. The most
recent guidelines of the European Respiratory
Society [16] and the revised national guidelines
of South Africa (C. Feldman, personal communi-
cation) also recommend aminopenicillins as ﬁrst-
line therapy.
At least in the UK, the approach of using amox-
icillin has the advantage of interfering least with
the established practice of primary-care physi-
cians, in whom a widespread switch to another
antibiotic class (e.g. the tetracyclines) would be
difﬁcult to achieve. It also avoids widespread use
of ﬂuoroquinolones, which is likely to drive resis-
tance (the spread of pneumococcal macrolide
resistance following widespread macrolide use
in recent years is already a concern) [33,34]. In
fact, ﬂuoroquinolones are restricted in the new
BTS guidelines as alternative agents for use in
hospitalized patients who have failed community
management.
Influence of resistance
The clinical and socioeconomic impact of antibio-
tic resistance in bacteria implicated in CAP is
discussed in detail elsewhere in this supplement
[35]. Here we will focus on the clinician’s perspec-
tive as to how this translates to an inﬂuence on
prescribing. Potentially, the most important issue
for outpatient CAP management is penicillin and
multidrug resistance in S. pneumoniae. However,
physicians are often sceptical as to the clinicalT
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relevance of resistance in relation to the treatment
of CAP. Failure to appreciate its importance may
be a result of how resistance is deﬁned and/or of
inconsistencies in recommendations made by var-
ious expert groups or committees regarding ﬁrst-
line therapy for CAP.
By convention, resistance is usually deﬁned on
the basis of in vitro testing. Surveillance studies are
certainly crucial to the identiﬁcation and monitor-
ing of resistance in vitro. However, these data are
of limited practical value to clinicians because they
tend to be based on a selective sample (often from
hospitalized patients). Moreover, the samples are
not necessarily from the local population treated
by the clinician and the data are not ‘real-time’.
Consequently, resistance surveillance data are
generally not representative of the situation at
the point of prescribing. Importantly, surveillance
data are not linked to the matter of most concern to
the clinician—i.e. clinical infection. Essentially, the
clinician is more concerned with ‘antibiotic-resis-
tant disease’—which may have causes other than
simply in vitro resistance among target patho-
gens—rather than antibiotic-resistant organisms.
For clinical purposes, in vitro minimum inhibi-
tory concentration (MIC) breakpoints must be
interpreted in relation to the concentration and
pharmacodynamic effects of the antibiotic at spe-
ciﬁc infection sites. The original breakpoints for
b-lactam resistance in S. pneumoniae are of rele-
vance in the context of the low cerebrospinal ﬂuid
penetration achieved by these agents in patients
with meningitis, and middle-ear penetration in
relation to pneumococcal otitis media. They have
been of questionable relevance in the management
of RTIs because b-lactams reach far higher con-
centrations in blood and lung tissue. As a result, b-
lactams can eradicate even ‘nonsusceptible’
(although perhaps not highly resistant) strains
from the lungs. Evidence from published studies
conducted in Europe [36–38], North America [39],
Latin America [40], Asia [41,42] and South Africa
[43] suggests that penicillin nonsusceptibility
(MIC> 0.1mg/L) does not signiﬁcantly impair
the efﬁcacy of penicillin, ampicillin, or amoxicillin
in the treatment of pneumococcal pneumonia in
hospitalized patients. One study did show an in-
creased risk of suppurative complications in
patients with bacteremic pneumonia caused by
penicillin-nonsusceptibleS. pneumoniae [44]. Impor-
tantly, there are relatively few data from patients
withCAPcausedbypneumococciwithhigher-level
resistance (MIC> 4mg/L), which are increasingly
prevalent andmore likely toproduce clinical failure
[21,25,45]. Moreover, there are few data concerning
the impact of resistance on the effectiveness of oral
antibiotic treatment for outpatient CAP.
This discrepancy between in vitro resistance
and clinical outcome is reﬂected in the guidelines
of the BTS [24] and others [46], in which b-lactams
remain recommended agents for the empiric out-
patient treatment of CAP, but at an increased
dosage compared with earlier recommendations.
The IDSA guidelines also acknowledge that
b-lactams are appropriate for pneumococcal
CAP, while recommending coverage against aty-
pical organisms for empiric therapy when the
cause is unknown. This underlines the fact that
the differences between the BTS and North Amer-
ican guidelines regarding initial empiric therapy
are a result of differences in interpretation of the
relative frequency and signiﬁcance of etiologic
agents and their susceptibility to recommended
therapies, as well as the recognized difﬁculties of
altering prescribing practices in primary care. It
also emphasizes the importance of severity assess-
ment, for which resistance is only one of several
possible causes, in deﬁning the choice of therapy.
Likewise, it reﬂects the variations in medical prac-
tice that frequently inﬂuence recommendations in
the absence of data supporting change.
Despite the high prevalence of in vitro macro-
lide resistance in S. pneumoniae in many areas of
the world [33], few studies have evaluated the
clinical impact of this development. Pharmacoki-
netic/pharmacodynamic analysis is more com-
plex for macrolides than for b-lactams because
of the intracellular concentration of the former
[47]. It has been suggested that the modest levels
of resistance (MIC 1–32mg/L) associated with
efﬂux-mediated macrolide resistance—the domi-
nant mechanism in North America (Table 4)
[48–54]—might be overcome by adequate macro-
lide doses [25]. However, high-level resistance
(MIC 64mg/L) caused by erm-mediated riboso-
mal alteration in the MLSB phenotype, which is
dominant in Europe and South Africa, might be
insurmountable using clinical dosages. Reports of
failure and breakthrough bacteremia during out-
patientmacrolide therapy for pneumococcal pneu-
monia have recently been published, although the
number of cases is small [55,56]. Other recent data
indicate that macrolide resistance is associated
with clinical failure in a minority of documented
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infections [57,58]. More widespread reports of fail-
ure may occur as high-level macrolide resistance
becomes more common [47].
Resistance to the newer ‘respiratory’ ﬂuoroqui-
nolones is not yet a major inﬂuence on prescribing
guidelines for CAP. However, reports of ﬂuoro-
quinolone resistance in Canada [59,60] and Hong
Kong [61,62] give reason for concern over the
more widespread use of these agents. Evidence
suggests that exposure to ﬂuoroquinolones is
associated with increased risk of subsequent infec-
tion or colonizationwith ﬂuoroquinolone-resistant
S. pneumoniae [63]. Fluoroquinolone resistance has
been linked to the clinical failure of these agents in
pneumococcal nosocomial lower RTIs [60] and
CAP [64].
Further research is required to establish the
clinical impact of antibiotic resistance among other
pathogens responsible for CAP, in addition to
S. pneumoniae. Ideally, prospective studies com-
paring treatment outcomes in microbiologically
documented infections by high-level resistant
and susceptible bacteria are required. Studies link-
ing in vitro data and clinical outcome are challen-
ging and expensive to perform, and distinguishing
adverse outcomes directly attributable to resis-
tance may be challenging. Such data are clearly
important both in the management of individual
patients and in the development of guidelines and
other prescribing support systems. Only when
knowledge concerning the clinical impact of resis-
tance is integrated with better etiologic data and
antibiotic susceptibility surveillance data will it
be possible to begin to deﬁne the prevalence of
resistance that should trigger a change in recom-
mended empiric antibiotic prescribing.
Dosage and duration
Data are also required on the impact of the ther-
apeutic choice, i.e. on outcome relative to appro-
priate vs. inappropriate therapy. This in turn
requires a consistent deﬁnition of appropriate ther-
apy. Appropriate therapy is not only a matter of
antibiotic selection, but also extends touncertainties
regarding the optimal dosage of some agents and in
particular to the duration of antibiotic therapy.
Uncertainty over the correct dosage may arise
both from our limited knowledge and from inter-
national variations in antibiotic susceptibility. The
BTS has now doubled its recommended dosage of
amoxicillin (to 0.5–1 g every 8 h) [24] in light of the
rising prevalence of penicillin resistance in S. pneu-
moniae in the UK. This dosage now concurs with
dosage recommendations in France [65] and Spain
[13], where the prevalence of penicillin-resistant
pneumococci has been high formany years [33,66].
Although higher dosages add to the cost of treat-
ment and increase the potential for adverse events,
these are considered less signiﬁcant than the
potential cost of treatment failure. Of course, the
need for increased doses may have potential dis-
advantages in terms of the tolerability of therapy.
Unless there are sound scientiﬁc reasons to the
contrary, the pharmaceutical industry in different
nations should be encouraged to standardize
recommended dosages.
The optimal duration of therapy for CAP is
poorly deﬁned. Indeed, appropriate controlled
Table 4 Prevalence and mechanism of macrolide resistance in Streptococcus pneumoniae in selected countries
Country Reference
Year
of study
No. of
isolates
Prevalence of
macrolide resistance
Mechanism of resistance
Efflux Target site Both
Africa
S. Africa McGee et al. [48] 1999 118 NDa 13% 57% 30%
Asia
Hong Kong Ip et al. [49] 1994–98 197 80% 73% 27%
Europe
Belgium Descheemaeker et al. [50] 1995–97 100 33% 9% 91% —
Italy Oster et al. [51] 1997 302 33% 6% 94% —
North America
Canada Johnston et al. [52] 1993–96 ? 3% 56% 43% —
USA Doern et al. [53] 1997–98 1601 19% 71% 27% —
aPrevalence in 1999 in the Alexander Project (n¼ 121 isolates) was 23% [54]
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trials have not been performed to support cur-
rent expert opinion recommendations for 1–2
weeks of treatment [21–24]. Should shorter
courses than those used presently prove to be
clinically and bacteriologically effective, this could
have a signiﬁcant impact on reducing the vol-
ume of antibiotic usage, the effect of such agents
on the normal bacterial ﬂora, and the cost of
therapy.
UPPER RESPIRATORY TRACT
INFECTIONS
Acute upper RTIs (URTIs) account for a substan-
tial proportion of total community antibiotic con-
sumption in adults and children [1–3]. Since URTIs
are often not caused by bacteria, these conditions
are a primary source of antibiotic overuse and
misuse in the community [1–3]. However, antibio-
tics do provide signiﬁcant beneﬁts in certain
patients with bacterial URTIs. The challenge for
physicians, and amajor aspect of published guide-
lines for the management of these infections, is to
identify patients in whom antibiotic therapy is
warranted.
Pharyngitis
Formal evidence-based guidelines for the diagno-
sis and management of pharyngitis include those
published by the IDSA [67], the American Heart
Association [68] and, most recently, the American
College of Physicians and the American Society of
Internal Medicine [69,70].
Most cases of acute pharyngitis are caused by
viral infection. However, approximately 10% of
cases in adults and approximately 15–30% of cases
in children are caused by group A b-hemolytic
streptococci (GABHS, primarily Streptococcus pyo-
genes) [66,71–73]. Although there are other bacter-
ial causes of pharyngitis [74], these are uncommon
and are not associated with suppurative, nonpus
complications such as rheumatic fever and glo-
merular nephritis. In patients with GABHS phar-
yngitis, antibiotics reduce the risk of suppurative
complications and the duration of symptoms
[69,75]. The prevention of rheumatic fever is
now of limited importance in Western countries
because of the low incidence of this complication
[76]. However, rheumatic fever remains of concern
in developing countries [76] and in certain regions
of Australia [77].
Diagnosis
The best way to differentiate patients with GABHS
from thosewith nonbacterial pharyngitis has yet to
be deﬁned. Some guidelines have recommended
that physicians should await the results of a throat
swab culture before prescribing an antibiotic for
pharyngitis [67,68]. However, as in CAP, micro-
biologic cultures are of limited use in the initial
decision to prescribe an antibiotic. Throat culture
results take 2–3 days to obtain, are subject to meth-
odologic variations, and cannot differentiate
between patients with acute infections and those
who are merely carriers of GABHS [67,69]. Evi-
dence therefore suggests that physicians tend to
base the decision to use antibiotics in patients with
pharyngitis on clinical grounds [78].
A number of scoring systems have been devel-
oped to help guide physicians in assessing the
likelihood of GABHS pharyngitis based on the
patient’s clinical presentation [72,79–84]. Most
recently, a scoring system developed by McIsaac
et al. in Canada for use both in adults and in
children (aged 3 years) has shown the potential
to reduce unnecessary antibiotic usage in clinical
practice (Table 5) [72,73]. The likelihood of GABHS
pharyngitis is then linked with recommendations
for disease management similar to those recently
issued by the American College of Physicians and
the American Society of Internal Medicine [69,70].
Disease management recommendations accord-
ing to the score were compared with observed
practice by family physicians in a prospective,
community-based study of adults and children
(n¼ 621) [73]. Compared with the usual care
observed, management recommended by the
score would have resulted in statistically signiﬁ-
cant reductions of over 80% in the numbers of
Table 5 Scoring system designed to identify patients with
sore throat who require antibiotics [72]
þ1 point for: Temperature 38 8C
Absence of cough
Tender anterior cervical adenopathy
Tonsillar swelling/exudate
Age 15 years
1 point for: Age 45 years
Total score
1 Neither antibiotics nor culture required
2–3 Take culture, base antibiotic decision on
result
4 Initiate antibiotics
immediately or take culture
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antibiotic prescriptions and unnecessary antibiotic
prescriptions and of 40% in the use of throat
cultures (all P< 0.01) (Figure 1). Using the score
would not have signiﬁcantly affected antibiotic
usage in children, although it would have reduced
the number of throat cultures by 28% (P< 0.01).
Beingsimple touse, the scorecardcanbepartially
completed in the physician’s waiting room by the
patient or, in the case of children, the parent. This
type of self-assessment, consistent with a more
shared-decision approach to management [85],
mayhelp tochangepatients’perceptionsof theneed
for antibiotic therapy. Even if the physician com-
pletes the score card, it can still be used to help
explain why an antibiotic will not be given.
Rapid streptococcal antigen tests are another
means of identifying patients with GABHS infec-
tion. These tests showmoderate to good speciﬁcity
and selectivity, depending on the setting and on
the particular test used [69], and they may be
beneﬁcial as adjuncts to clinical assessment. For
example, they may be used to support the diag-
nosis of infection in patients whose clinical score
predicts a high likelihood of infection [69]. How-
ever, these tests are not used widely in many
countries and further research and development
are required to deﬁne their optimal role. In addi-
tion, they do not provide information on antibiotic
susceptibility where this might be important, for
example in areas where macrolide resistance
among S. pyogenes is common.
Influence of resistance
The selection of antibiotics for the treatment
of GABHS pharyngitis has been reviewed in
detail elsewhere [86–89]. Penicillin (either oral or
intramuscular) remains the recommended ﬁrst-
line antibiotic owing to its narrow spectrum, efﬁ-
cacy, tolerability and cost [67–70]. A 10-day course
of penicillin is generally recommended [67–70,90].
Seven-day courses are used in some countries (e.g.
The Netherlands), but 3- and 5-day courses appear
insufﬁcient [91,92]. Other b-lactams (e.g. amoxicil-
lin, ampicillin, ﬁrst- and second-generation cepha-
losporins) havebeen showntobeat least as effective
as penicillin in eradicating GABHS.
In vitro resistance to penicillin has not been
documented in GABHS. Nevertheless, clinical
and bacteriologic failure with penicillin is increas-
ingly common [89]. Several explanations have
been suggested, including poor adherence to the
10-day treatment regimen, re-infection, co-patho-
genicity by other penicillin nonsusceptible bac-
teria, eradication of protective ﬂora, and
streptococcal penicillin tolerance [89].
A growing body of evidence supports the efﬁ-
cacy of shorter antibiotic courses (e.g.5 days), for
instance with certain cephalosporins [86,93]. If
short-course regimens facilitate better compliance,
theymay be preferable in some circumstances [89].
Moreover, they might avoid the increased risk
of pharyngeal carriage of penicillin-resistant
S. pneumoniae that has been associated with longer
b-lactam treatment durations (>5days) [94]. How-
ever, there remains some concern regarding the
equivalence of cephalosporins with penicillin
treatment [86].
Macrolides are also effective and are generally
recommended as alternatives to penicillin in aller-
gic patients. Although macrolide resistance in
GABHS is uncommon in North America, evidence
that this is changing has been published [95]. This
is certainly a more important consideration in
certain other countries. The prevalence of macro-
lide resistance in GABHS has been reported to be
20% in Italy [96–98], Spain [99,100], Portugal
[101], Finland [102], Hong Kong and Korea [103].
Macrolide resistance inGABHShas been correlated
with widespread macrolide usage [104–106] and
with clinical failure of pharyngitis therapy [102].
Tetracyclines and sulfonamides are not recom-
mended for the treatment of GABHS because high
levels of resistance exist to these agents.
Acute sinusitis
In recent years, guidelines for the diagnosis and
management of acute bacterial sinusitis have been
Figure 1 Potential reductions in antibiotic usage and throat
culture orders obtained in adults with sore throat using a
clinical sore throat score vs. physician’s judgement [72].
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published by numerous groups [107–114]. Many
of these have taken an explicitly evidence-based
approach, although evidence regarding treatment
is often limited.
The microbiologic etiology of acute sinusitis is
reasonably well deﬁned [108,112]. Most cases are
caused by viruses and do not require antibiotics.
Bacterial infection of the sinuses results from
obstruction of nasal drainage, which is often the
result of a primary viral infection. The most com-
mon infecting bacteria are S. pneumoniae and
H. inﬂuenzae, which together account for around
70% of cases. Anaerobes, Staphylococcus aureus,
S. pyogenes, Moraxella catarrhalis, and Gram-nega-
tive bacteria are uncommon causes in adults,
although M. catarrhalis may be responsible for
approximately one-quarter of cases in children.
Diagnosis
The challenge for the physician is to identify those
patients with acute bacterial sinusitis in whom
antibiotics provide signiﬁcant symptomatic bene-
ﬁt over placebo [115]. The gold standard criterion
for diagnosing bacterial sinusitis is a positive bac-
terial culture of nasal secretions obtained by sinus
puncture [108,111,113]. However, this procedure is
not routinely performed in primary-care clinical
practice.
Unfortunately, it is very difﬁcult to distinguish
between viral and bacterial sinusitis on clinical
grounds. Certain clusters of symptoms may be
helpful, but the most useful criterion seems to
be the duration of illness [108,111–113]. Bacterial
sinusitis is uncommon in patients with symptoms
lasting less than 10 days. Indeed, the United States
Food and Drugs Administration speciﬁes an ill-
ness duration of 10 days as an enrolment criter-
ion for clinical trials for the management of
sinusitis. In general, however, a diagnosis of acute
bacterial sinusitis may be made in adults and
children with symptoms of a viral URTI that has
not improved after 10 days or has worsened after
5–7 days. If the use of antibiotics is delayed, the
patient should receive reassurance and sympto-
matic treatment in the meantime. Not all cases will
follow this typical progression and so physicians
must rely on their clinical judgement when delay-
ing antibiotic therapy.
The approach of delaying antibiotic treatment is
likely to result in some patients with bacterial
infection being denied therapy that might have
improved their symptoms earlier. This risk must
be weighed against the likelihood that widespread
adoption of delaying antibiotic therapy is likely to
reduce the volume of unnecessary antibiotic usage
in patients with nonbacterial infections. It is also
important to remember that when applying such
generalized recommendations, the patient’s parti-
cular medical history must be considered. For
example, immediate antibiotic therapy may be
warranted in patients with a history of recurrent
bacterial sinusitis.
Influence of resistance
Regrettably, current evidence-based guidelines for
the antibiotic treatment of acute bacterial sinusitis
are supported by relatively few well-designed,
double-blind, placebo-controlled, randomized
clinical trials [116]. Amoxicillin is generally recom-
mended as the ﬁrst-line empiric treatment
[108,110,111,113,114]. A 10- to 14-day antibiotic
course is recommended, although shorter courses
of newer agents have been used with similar
efﬁcacy [108,117]. As with other RTIs, the impact
of antibiotic resistance may not be obvious to the
practicing clinician. Most episodes of sinusitis are
self-limited and require only symptomatic relief.
Even bacterial infections are often self-limited,
depending on the pathogen and its antimicrobial
susceptibility.
The impact of resistance on outcomes in patients
treated with antibiotics for sinusitis is difﬁcult to
estimate at present. Physicians treating patients
who have acutemaxillary sinusitis rarely know the
etiologic agent or its susceptibility to the antibiotic
used for treatment. Few data are available from
clinical trials comparing new antibiotics to stan-
dard therapy because these studies often exclude
patients infected with resistant pathogens. More-
over, data from past studies are of limited rele-
vance owing to differences in the deﬁnition and
management of sinusitis. In the past, the use of
antibiotics early in the course of the illness would
often result in the treatment of viral infections,
which would be expected to mask the impact of
antibiotic therapy and of antibiotic resistance. As
already outlined, it is now recommended that
antibiotic therapy should be reserved for patients
who are symptomatic for at least 7 days to isolate
patients with bacterial infections who are most
likely to beneﬁt from treatment [113]. There
remains a need for studies designed to assess
the impact of antibiotic resistance in this patient
population.
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Otitis media
Although this paper has concentrated mainly on
the management of RTIs in adults, we cannot
ignore the contribution made by antibiotic usage
for otitis media in children to resistance of RTI
pathogens in the community. Patterns of antibiotic
usage for otitis media vary considerably between
different countries. For example, approximately
30% of patients with otitis media receive antibio-
tics in The Netherlands, compared with over 90%
of patients in the USA, Great Britain, Switzerland,
Israel and Australasia [118]. There is also evidence
of considerable variation in prescribing practice
within individual countries, for example as
reported in France [119], Spain [120] and the
USA [121].
Relatively few formal, evidence-based guide-
lines for the management of acute otitis media
have been published. However, various experts
have made recommendations [122–124] and the
CDC has published guidelines [109], most recently
in response to the increase in penicillin resistance
in S. pneumoniae [125].
The role of antibiotics in the management of
otitis media is somewhat controversial. Meta-
analyses have suggested that they provide only
modest beneﬁts [126–128]. However, evidence
from double-tympanocentesis studies, in which
middle ear ﬂuid is sampled before and after anti-
biotic treatment, shows that bacterial eradication
contributes to improved clinical outcomes in cul-
ture-positive patients [46,129]. Therefore, the lack
of beneﬁt seen in some trials may be a result of the
inclusion of patients in whom antibiotic therapy
was not warranted or by the use of agents with
poor antibacterial activity [130]. Antibiotics may
have a particularly important role in otitis media
in developing countries, where the risk of compli-
cations is higher [121].
Diagnosis
One approach to rationalizing antibiotic use in
otitis media, advocated by the CDC [109], is to
differentiate between patients with acute otitis
media, in whom initial antibiotic therapy is indi-
cated, and those with otitis media with effusion, in
whom it is not. Delaying antibiotic therapy until
bacterial infection is conﬁrmed microbiologically,
in the same manner recommended for acute bac-
terial sinusitis, is more controversial for otitis
media. This approach has been pioneered in The
Netherlands and the Dutch College of Family
Doctors recommends the use of symptomatic
treatment for 3 days in patients aged >2 years
and up to 2days in those aged between 6months
and 2 years, before antibiotic treatment is consid-
ered [131,132]. Unfortunately, this approach might
not be feasible or cost-effective in many countries
because of differences in health-care delivery and
may be not be generally accepted in other coun-
tries, for instance in North America. Although
experts agree that over-diagnosis (compared with
conformation using tympanocentesis) may occur
in 40–80% of patients, it is still felt that the beneﬁt
seen in the small subset of patients whose infec-
tions warrant antibiotics justiﬁes their widespread
use.
Influence of resistance
A large multinational study recently conﬁrmed
that the main bacterial pathogens implicated in
otitis media are S. pneumoniae and H. inﬂuenzae
[133]. However, there was considerable variation
in the distribution of these pathogens between
the three geographic regions studied: S. pneumo-
niae was isolated more commonly in Central and
Eastern Europe than in Israel and the USA, while
H. inﬂuenzae was more common in Israel and the
USA. The selection of initial empiric antibiotic
therapy for otitis media is increasingly inﬂuenced
by the spread of clinically signiﬁcant bacterial
resistance [129,130,134]. Indeed, resistance is
now regarded as the main reason for treatment
failure.
Amoxicillin is generally recommended for ﬁrst-
line use [122,124,125]. However, in the aforemen-
tioned multinational etiologic study, composite
in vitro susceptibility rates to amoxicillin among
S. pneumoniae,H. inﬂuenzaeandM.catarrhalis ranged
from only 62% in the USA to 89% in Central
and Eastern Europe [133]. Resistance rates found
regionally in each organism are shown in Figure 2.
Intermediate penicillin resistance in S. pneumoniae
causing otitis media increases the risk of bacterio-
logic failure with amoxicillin and oral cephalospor-
ins[134–136]. Inaddition,resistancetomacrolides in
S. pneumoniae impairs the bacteriologic efﬁcacy of
these agents [134,136].
The efﬁcacy of amoxicillin is also reduced by
b-lactamase-mediated resistance in H. inﬂuenzae
[46]. Bacteriologic failure may also occur with
azithromycin against H. inﬂuenzae, although this
is not because of resistance. Rather, intracellular
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accumulation of the drugmay result in insufﬁcient
extracellular concentrations in the middle ear
[46,137]. This underlines the importance of com-
bining pharmacokinetics and pharmacodynamics
when evaluating the efﬁcacy of antibiotics against
infections caused by resistant organisms. Further
research is required to link better the resistance
and efﬁcacy in otitis media. Ideally, studies must
be conducted using the double tympanocentesis
method and by stratifying patients by age and
infection severity [130] and by the type and anti-
biotic susceptibility of the infecting pathogen.
How does the physician know which patient
may have a resistant infection? As in CAP, resis-
tance is linked with disease management in otitis
media using relatively ‘soft’ risk factors. In otitis
media, these include recent antibiotic use, young
age, day-care attendance and prior hospitalization
[133,134]. As for CAP, the use of high doses of
amoxicillin (80–90mg/kg/day) has been recom-
mended to overcome b-lactam resistance [109].
Otherwise, more potent and broad-spectrum
agents are recommended for treatment failure.
This brings us back to the issue of deﬁning the
prevalence of resistance that should prompt a
change in empiric prescribing. In areas where
there is a high prevalence of resistance (>10%)
in important pathogens, it is important to develop
criteria to identify patients who are at greatest risk
for being infected with resistant organisms (e.g.
previous antibiotics in the last 3months and atten-
dance at day centers).
As for other RTIs, there may be scope for redu-
cing the duration of antibiotic treatment for acute
uncomplicated otitis media to aid compliance.
Evidence indicates that the duration can be
reduced from 10 to 5days without a signiﬁcant
loss of efﬁcacy [119,138].
IMPLEMENTING GUIDELINES
There is little point in developing treatment guide-
lines unless they are widely applied in routine
clinical practice. Despite the increasingly scientiﬁc,
evidence-based approach taken in the develop-
ment of current guidelines for the management
of community-acquired respiratory tract infec-
tions, many physicians do not use them for a
complex variety of physician-, patient- or sys-
tem-related reasons [139–145]. For example, bar-
riers to physician adherence identiﬁed by Cabana
et al. in their review of study literature [140] may
be grouped in terms of:
 knowledge, e.g. lack of awareness or familiarity
with the guidelines among physicians;
 attitudes, e.g. disagreementwith guidelines, lack
of trust of guidelines (low ‘outcome expectancy’)
and lack of self-conﬁdence (or ‘self-efﬁcacy’)
among physicians;
 behavior, e.g. inﬂuence of factors related to the
patient, the health-care service environment or
the guidelines themselves.
Therefore it is important to consider how phy-
sicians’ knowledge of, and adherence to, treatment
guidelines can be maximized.
Developmental issues
This process begins at the research and develop-
ment stages. Some national guidelines, for exam-
ple those produced in North America and the UK,
have proved inﬂuential in many countries other
than those of their origin. However, guidelines
should ideally be produced on a national basis
by individual countries. This is important for two
main reasons. First, national guidelines can take
account of the local etiology, resistance patterns,
health-care delivery, drug availability and licen-
sing features of the individual country concerned.
For example, although the North American CAP
guidelines have been inﬂuential in Eastern Eur-
ope, the guidelines are modiﬁed locally according
to national susceptibility data. For example in
Poland, high rates of resistance to cotrimoxa-
zole among H. inﬂuenzae and S. pneumoniae, and
to tetracyclines among all Gram-positive cocci,
Figure 2 Susceptibility to amoxicillin of middle-ear iso-
lates from children with acute otitis media in Central and
Eastern Europe, Israel and the USA [133]. Susceptibility
breakpoints: 0.5mg/L for S. pneumoniae and 4mg/L for
H. influenzae and M. catarrhalis. Numbers of isolates are
shown in brackets.
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preclude recommendation of these agents for
empiric therapy. Moreover, prescribing is heavily
inﬂuenced by the production and importation of
relatively cheap, generically produced antibiotics,
as reimbursement is made only for the least-
expensive version available (W. Hryniewicz, per-
sonal communication).
Second, local development is important in
securing physicians’ familiarity and agreement
with the guidelines. This in turn is likely to
improve the likelihood of widespread adherence.
For example, during the development of the
revised BTS guidelines for CAP management
[24], the perspective of the user was built into
the process of development at an early stage.
Consultation was held with 263 hospitals, with
professional societies and with agencies providing
health-care guidance.
Various different professional bodies and gov-
ernmental authorities within a particular country
are likely to have an interest in developing
national guidelines for community-acquired RTIs.
This can lead to the publication of multiple sets of
guidelines from different groups. For example in
the USA, separate CAP guidelines have been
issued by the IDSA [21], ATS [22] and CDC [25].
These groups each have access to the same evi-
dence base. However, weaknesses in these data
necessitate value judgements that can introduce
variation between the different guidelines. There-
fore, in addition to providing an ‘information
overload’ to busy health-care workers, multiple
guidelines may also cause confusion and perhaps
even disillusionment with their usefulness. Ide-
ally, all national bodies with an interest in devel-
oping guidelines should co-operate to provide a
single statement that can beneﬁt from the expertise
and opportunities for dissemination offered by
each group. As an example, in South Africa a
single guideline publication for CAPmanagement,
developed by pulmonologists, clinical microbiol-
ogists, infectious disease physicians and other
groups [17], is nationally accepted by government
and included in undergraduate medical education
curricula (C. Feldman, personal communication).
Recent surveys of pediatricians in the USA may
help to improve the design of guidelines. In one
survey [139], only 50% of pediatricians (n¼ 555)
were aware of guidelines for the treatment of otitis
media with effusion issued by the Agency for
Healthcare Policy and Research. In another, only
19% (n¼ 627) used guidelines for otitis media
[143]. The most commonly cited problems with
guidelineswere their complexity, rigidity (i.e. their
failure to allow for clinical judgement), and poten-
tial use in litigation. Results from these studies
allow us to identify certain features of guidelines
that may improve the likelihood of physician com-
pliance (Table 6).
Scientiﬁc evidence is not the only inﬂuence on
prescribing decisions. Another important factor is
the physician–patient relationship.Where feasible,
we would also encourage groups developing
guidelines to consult with patients’ organizations
to incorporate amore patient-centered approach to
the management of community-acquired RTIs
[85].
Implementation
Changing medical practice to conform to guide-
lines is a challenging endeavor that is not
addressed by the current published RTI guide-
lines. An initial consideration is the manner in
which guidelines are disseminated. Publication
of guidelines and of the research supporting them
in the medical literature is certainly important.
However, while this type of publication might
inform specialists, it is likely to have limited inﬂu-
ence on primary-care physicians in the commu-
nity. Distillation of guidelines into a simple, user-
friendly format available at the point of prescrib-
ing is vital. For example, the revised BTS guide-
lines for CAP management [24] are available on
a laminated card that is convenient to carry.
Guidelines can also be disseminated by letter to
physicians and in other nonspecialist medical pub-
lications (e.g. journals, bulletins and newsletters).
Unfortunately, physicians’ behavior in the man-
agement of RTIs is unlikely to be changed simply
by the distribution of guidelines [142]. In general,
information transfer via written materials alone is
Table 6 Features of guidelines that may improve the
likelihood of physician compliance according to surveyed
pediatricians in the USA [139,143]
Simplicity
Feasibility/applicability
Flexibility (i.e. allowance for personal clinical judgement)
Testing (i.e. shown to improve outcomes)
Intended to improve quality of care
Not intended to reduce costs
Not used in litigation or disciplinary actions
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relatively ineffective in inducing change in med-
ical practice [146–149]. This must be supported by
other interventions, such as individual or group
education, reminders and feedback [146–148,150–
152]. Research conducted to date provides limited
guidance on how change can best be achieved.
Although many methods of behavior change have
shown effectiveness in some studies [146–148,150–
153], overall there is considerable variability in the
interventions, the study designs and in the results
obtained.
Educational outreach visits (or ‘academic detail-
ing’) and interactive educational meetings or
workshops are promising approaches to inﬂuen-
cing medical practice [150,152], including antibio-
tic prescribing in the community [154,155]. For
example, in a recent controlled study involving
112 primary-care physicians in the UK, educa-
tional visits by a pharmacist adviser resulted in
signiﬁcant improvements in antibiotic prescribing
patterns, as deﬁned by local practice guidelines
[154]. In the USA, an education program on anti-
biotic usage combined educational outreach visits
by a physician peer leader with the provision of
information to patients (via a mailed compact disk
and materials in physician waiting rooms) [155].
The programwas evaluated during a 2-year study;
signiﬁcant improvements in antibiotic usage were
achieved in children in the intervention year com-
pared to the baseline year.
Other evidence suggests that continuing medi-
cal education materials and conferences may have
less impact than systematic practice-based inter-
ventions [147]. Generally, it appears that educa-
tional interventions are more likely to succeed if
they are multifaceted and tailored to the speciﬁc
setting [147,148]. It is also important to identify
and minimize any barriers to the application of
guidelines by physicians, e.g. practice organiza-
tion, lack of time, negative ﬁnancial incentives
[142,148].
OTHER DECISION-SUPPORT
SYSTEMS
Publishedguidelinesforpatientmanagementrepre-
sent only one type of prescribing decision-support
system. In recent years, advances in information
technologyhave creatednewopportunities fordeli-
very of more dynamic, computer-assisted forms
of guidance at the point of prescribing. Important-
ly, these systems can be integrated with local
epidemiologic and microbiologic data. In addition
to improvingpatientcare, thesesystemscancapture
usefuldata regardingprescribing trends, adherence
to guidelines, etc.
For example, at the LDS Hospital in Salt Lake
City, USA, hospital antibiotic treatment re-
commendations have been implemented via a
computer-assisted decision-support system that
incorporates locally derived guidelines for anti-
biotic usage, patient medical records, epidemiolo-
gic information, feedback and the opportunity for
physicians to use their own clinical judgement
[156,157]. According to observational research,
the implementation of this system has been asso-
ciated with improvements in the quality of inpa-
tient antibiotic prescribing (e.g. in terms of
excessive drug dosages, use of discordant therapy
according to antibiotic susceptibility, use of inap-
propriate drugs in allergic patients, incidence of
antibiotic-induced adverse events), and reductions
in the length of hospital stay and in treatment costs
[156,157]. Bacterial resistance patterns were
reported to have stabilized during one evaluation
period [156]. In addition, a point-of-care informa-
tion system in the USA providing evidence-based
advice regarding antibiotic use for otitis media has
been tested in the pediatric outpatient setting.
Evidence from a randomized, controlled trial sug-
gests that this type of system can signiﬁcantly
improve antibiotic prescribing practice [158].
There is considerable interest in the USA in using
palm-held computers to provide this type of data
conveniently at the bedside.
Evidence from other types of infection suggests
that interventions of this type may need to be
tailored to speciﬁc medical conditions. An electro-
nic medical record system giving real-time med-
ical history data and advice regarding disease
management improved the quality of care and
reduced costs in health-care personnel exposed
to bodily ﬂuids [159]. However, a corresponding
intervention in the treatment of febrile children
did not signiﬁcantly affect the quality of care or
health-care costs [160].
Applying such systems on a larger scale in the
primary-care setting is more challenging. The Uni-
ted Kingdom National Health Service is currently
implementing a national online prescribing sup-
port system known as PRODIGY [161]. This sys-
tem provides primary-care physicians with online,
desktop prescribing support covering a range of
disease states, including RTIs.
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AUDITING GUIDELINES
Ideally, the effects of guidelines and other pre-
scribing support systems should be audited so that
best practice can be identiﬁed and resources allo-
cated to the most cost-effective interventions. Sev-
eral end-points could be assessed with regard to
the impact of guidelines for outpatient anti-
biotic treatment of community-acquired RTIs,
including:
 medical practice (e.g. antibiotic prescribing,
usage of tests);
 clinical outcomes (e.g. reconsultation, hospitali-
zation, complications);
 bacterial resistance patterns;
 cost [162,163].
The issue of audit has received relatively little
attention within the published guidelines them-
selves and there are few recommendations on how
assessment should be performed. For example, the
IDSA recommends ﬁve performance indicators in
its CAP guidelines [21] and seven indicators of
quality of care have been recommended for
patients with acute pharyngitis [67].
Audits of practice guidelines and care pathways
for patients hospitalized with CAP have shown
that, while compliance can be a problem
[144,164,165], these strategies can improve the
quality of health-care and reduce health-care
resource consumption [162,166,167]. Fewer data
are available in the outpatient setting. In the
USA, Gleason et al. evaluated the medical out-
comes and costs associated with the use of the
national ATS guidelines for outpatient CAP man-
agement in 864 patients [168]. Their ﬁndings sup-
ported the guidelines in patients aged <60 years,
in whom recommended therapy resulted in cost
savings with no worsening of clinical outcomes.
However, treatment costs in patients aged
>60 years or with co-morbidity were signiﬁcantly
increased—without any evidence for improved
outcomes—by recommended therapy.
In Denmark, the distribution of practice guide-
lines was coupled with a 3-year audit of antibiotic
prescribing for RTIs in the community [169]. Anti-
biotic prescribing for most infections fell in both
the intervention and control groups, but a lasting
decrease in prescriptions for sinusitis and an
improvement in the penicillin/broad-spectrum
antibiotic ratio in sinusitis, bronchitis and pneu-
monia was seen in the intervention group. There is
also evidence that practice guidelines can improve
diagnostic practices in patients with URTIs [170].
However, Sonnad et al. found that guidelines
failed to change physicians’ belief or practices
regarding the need for diagnostic tests in patients
with sore throat [142], underscoring the need for
more comprehensive behavioral change strategies.
Relating practice guidelines to changes in bac-
terial resistance patterns in the community—the
end-point of ﬁnal concern for this particular docu-
ment—will be difﬁcult. Bacterial resistance pat-
terns are inﬂuenced by a range of factors in
addition to antibiotic usage. Moreover, because
guidelines generally represent only one element
within programs of interventions aimed at redu-
cing bacterial resistance (as reviewed elsewhere
[171,172]), it might be impossible to discern their
speciﬁc contribution. Evidence supporting a
potential effect of guidelines was provided in Fin-
land, where speciﬁc recommendations for reduced
usage of macrolides for RTIs and skin infections in
outpatients, communicated via the national med-
ical journal and lectures at national and local
levels, resulted in a nationwide decline in macro-
lide usage between 1992 and 1996 [105]. This, in
turn, was associated with a signiﬁcant decrease in
the prevalence of erythromycin resistance in group
A b-hemolytic streptococci (from 18.5% of isolates
tested in 1992 to 8.6% in 1996), although a causal
relationship could not be established.
The practical implications of this Finnish study
are uncertain. Total antibiotic usage remained the
same during the study period, changes in resis-
tance patterns to other agents were not reported
and genotyping of bacterial strains was not per-
formed. Moreover, practice guidelines generally
aim to optimize antibiotic usage in a particular
setting, rather than simply to reduce usage of a
particular class of agents. Finally, the Finnish
experience was not sustained. Clearly, evidence
of the effect of practice guidelines on resistance
patterns, particularly in the community setting, is
still lacking and further research is required. Study
methods for this purpose (e.g. controlled trials,
controlled before and after studies, and inter-
rupted time series), together with criteria for asses-
sing the quality of the research, have recently been
reviewed by Davey et al. [163].
CONCLUSIONS
Optimal antibiotic usage in the treatment of com-
munity-acquired bacterial RTIs is hampered by the
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lack of simple diagnostic tests to conﬁrm bacterial
infection. Efforts must continue to develop meth-
ods by which the subset of patients with bacterial
infection, in whom antibiotics are of beneﬁt, can be
accurately and reliably identiﬁed. Bacterial resis-
tance is an increasing inﬂuence on the antibiotic
treatment of community-acquired RTIs. However,
the nature and extent of the challenge presented by
resistance remains unclear. Research is required to
deﬁne better the etiology of these infections, par-
ticularly CAP, and to link resistance and clinical
outcome to determine the level of resistance that
should trigger a change in empiric antibiotic pre-
scribing.
By encouraging prudent antibiotic use, the new
generation of treatment guidelines should aid in
controlling resistance in bacteria in the commu-
nity. However, the effect of treatment recommen-
dations on resistance patterns is an important, but
seldom discussed, gap in our knowledge. As it is
difﬁcult to differentiate antibiotics on the basis of
clinical efﬁcacy, their selection must be based on
their tolerability, drug interactions, availability,
cost and propensity to drive resistance. Recom-
mendations tend to opt for the least expensive,
most narrow-spectrum agent available. However,
with regard to resistance development, we do not
even have data to support this logic. Innovative
research to address these issues will require col-
laboration between microbiologists, physicians,
regulatory authorities and the pharmaceutical
industry. New antibiotics will continue to have a
role in infectious disease management, especially
where bacterial resistance compromises existing
therapies. The challenge is to ensure that these
agents are shown to be cost-effective as well as
efﬁcacious. Exclusive promotion of generic pre-
scribing is likely to limit the efﬁcacy of older
generic agents, thereby underscoring the need
for new compounds.
Given the major challenges in changing medical
practice, concentrated and sustained efforts are
needed to secure physicians’ knowledge of, accep-
tance of and use of treatment guidelines for RTIs.
Further research is required to establish the most
effective, and most cost-effective, means of imple-
menting and auditing guidelines. The emphasis
must be on optimizing, rather than simply redu-
cing, antibiotic use. Promising computer-assisted
approaches to prescribing support are now being
introduced. These systems are expected to
improve patient care and the quality of antibiotic
use, and it is hoped that they will be adopted more
widely in the future.
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